MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on March 28, 2006; DOI: 10.1124/mol.105.020198


This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.105.020198v1
70/1/227    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Briggs, C. A.
Right arrow Articles by Surowy, C. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Briggs, C. A.
Right arrow Articles by Surowy, C. S.


Received for publication October 21, 2005.
Revised March 15, 2006.
Accepted for publication March 21, 2006.

Untranslated Region Dependent Dependent Exclusive Expression of High-Sensitivity Subforms of {alpha}4{beta}2 and {alpha}3{beta}2 Nicotinic Acetylcholine Receptors

Clark A. Briggs 1*, Earl J. Gubbins 1, Michael J. Marks 2, C. Brent Putman 1, Rama Thimmapaya 1, Michael D. Meyer 1, Carol S. Surowy 1

1 Abbott Laboratories 2 University of Colorado

* Address correspondence to: E-mail: clark.briggs{at}abbott.com

Abstract

{alpha}4{beta}2 nicotinic acetylcholine receptors are recognized as the principal nicotine binding site in brain. Recombinant {alpha}4{beta}2 nAChR demonstrate biphasic concentration-response relationships with low- and high-EC50 components. This study shows that untranslated regions (UTR) can influence expression of high-sensitivity subforms of {alpha}4{beta}2 and & [alpha]3{beta}2 nAChR. Oocytes injected with {alpha}4 and {beta}2 RNA lacking UTR expressed biphasic concentration-response relationships for ACh with high- sensitivity EC50 values of 0.5 to 2.5 µM (14-24% of the population) and low-sensitivity EC50 values of 110-180 µM (76-86%). In contrast, message with UTR expressed exclusively the high-sensitivity {alpha}4{beta}2 nAChR subform with an ACh EC50 value of 2.2 µM. Additional studies revealed pharmacologic differences between high- and low-sensitivity {alpha}4{beta}2 subforms. While the antagonists dihydro-{beta}-erythroidine (IC50 3-6 nM) and methyllycaconitine (IC50 40-130 nM) were not selective between high-and low-sensitivity {alpha}4{beta}2, chlorisondamine, mecamylamine and d-tubocurarine were, respectively, 100-, 8-, and 5- fold selective for the & [alpha]4{beta}2 subform with low-sensitivity to ACh. Conversely, agonists that selectively activated the high- sensitivity {alpha}4{beta}2 subform with respect to efficacy as well as potency were identified. Further, two of these agonists were shown to activate mouse brain {alpha}4{beta}2 as well as the ferret high-sensitivity {alpha}4{beta}2 expressed in Xenopus oocytes. Using UTR-containing RNA, exclusive expression of a novel high-sensitivity {alpha}3{beta}2 nAChR was also achieved. These studies (a) provide further evidence for the existence of multiple subforms of {alpha}4{beta}2 nAChR, (b) extend that to {alpha}3{beta}2 nAChR, (c) demonstrate UTR influence on {beta}2-containing nAChR properties, and (d) reveal compounds that interact with & [alpha]4{beta}2 in a subform-selective manner.


Key words: Nicotinic cholinergic, Ion channel regulation


This article has been cited by other articles:


Home page
J. Neurosci.Home page
B. Tu, Z. Gu, J.-x. Shen, P. W. Lamb, and J. L. Yakel
Characterization of a Nicotine-Sensitive Neuronal Population in Rat Entorhinal Cortex
J. Neurosci., August 19, 2009; 29(33): 10436 - 10448.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. D. Son, F. J. Moss, B. N. Cohen, and H. A. Lester
Nicotine Normalizes Intracellular Subunit Stoichiometry of Nicotinic Receptors Carrying Mutations Linked to Autosomal Dominant Nocturnal Frontal Lobe Epilepsy
Mol. Pharmacol., May 1, 2009; 75(5): 1137 - 1148.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
N. B. Fedorov, L. C. Benson, J. Graef, P. M. Lippiello, and M. Bencherif
Differential Pharmacologies of Mecamylamine Enantiomers: Positive Allosteric Modulation and Noncompetitive Inhibition
J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 525 - 532.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
M. Moroni, R. Vijayan, A. Carbone, R. Zwart, P. C. Biggin, and I. Bermudez
Non-Agonist-Binding Subunit Interfaces Confer Distinct Functional Signatures to the Alternate Stoichiometries of the {alpha}4{beta}2 Nicotinic Receptor: An {alpha}4-{alpha}4 Interface Is Required for Zn2+ Potentiation
J. Neurosci., July 2, 2008; 28(27): 6884 - 6894.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
A. Kuryatov, J. Onksen, and J. Lindstrom
Roles of Accessory Subunits in {alpha}4{beta}2* Nicotinic Receptors
Mol. Pharmacol., July 1, 2008; 74(1): 132 - 143.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. Gotti, M. Moretti, N. M. Meinerz, F. Clementi, A. Gaimarri, A. C. Collins, and M. J. Marks
Partial Deletion of the Nicotinic Cholinergic Receptor {alpha}4 or {beta}2 Subunit Genes Changes the Acetylcholine Sensitivity of Receptor-Mediated 86Rb+ Efflux in Cortex and Thalamus and Alters Relative Expression of {alpha}4 and {beta}2 Subunits
Mol. Pharmacol., June 1, 2008; 73(6): 1796 - 1807.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
R. Zwart, A. L. Carbone, M. Moroni, I. Bermudez, A. J. Mogg, E. A. Folly, L. M. Broad, A. C. Williams, D. Zhang, C. Ding, et al.
Sazetidine-A Is a Potent and Selective Agonist at Native and Recombinant {alpha}4{beta}2 Nicotinic Acetylcholine Receptors
Mol. Pharmacol., June 1, 2008; 73(6): 1838 - 1843.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
R. M. Drenan, R. Nashmi, P. Imoukhuede, H. Just, S. McKinney, and H. A. Lester
Subcellular Trafficking, Pentameric Assembly, and Subunit Stoichiometry of Neuronal Nicotinic Acetylcholine Receptors Containing Fluorescently Labeled {alpha}6 and 3 Subunits
Mol. Pharmacol., January 1, 2008; 73(1): 27 - 41.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
L. Tapia, A. Kuryatov, and J. Lindstrom
Ca2+ Permeability of the ({alpha}4)3(beta2)2 Stoichiometry Greatly Exceeds That of ({alpha}4)2(beta2)3 Human Acetylcholine Receptors
Mol. Pharmacol., March 1, 2007; 71(3): 769 - 776.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. Moroni, R. Zwart, E. Sher, B. K. Cassels, and I. Bermudez
{alpha}4beta2 Nicotinic Receptors with High and Low Acetylcholine Sensitivity: Pharmacology, Stoichiometry, and Sensitivity to Long-Term Exposure to Nicotine
Mol. Pharmacol., August 1, 2006; 70(2): 755 - 768.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics